

# Citation Evidence Report

EB-1A Petition — Original Contributions of Major Significance

8 CFR § 204.5(h)(3)(v) · Criterion 5


## Srijani Basu

Associate Research Scientist, Columbia University

[Google Scholar profile](#)

**Generated 2026-05-21 by CiteMap.** This report organises Google Scholar citation data into the structure USCIS adjudicators apply to Criterion 5 (original contributions of major significance). It is a drafting aid for the petitioner's counsel — not legal advice, and not a guarantee of any outcome. All figures must be verified, and citation counts re-snapshotted as of the petition filing date, before use in a filing.

## A. Overview & Filtering Statement



### Filtering statement – methodology & limits

Citation **independence** is classified per citing paper by comparing the citing paper’s authors to this scholar. *Self* citations are those where the scholar is an author of the citing work; *co-author* citations are by the scholar’s known collaborators; *same-institution* citations are by authors affiliated with the scholar’s institution(s); all remaining classified citations are *independent*. Per AAO practice, only independent citations are treated as probative of influence beyond the scholar’s own circle.

**Known limitations – counsel must verify.** (1) Collaborator identification draws on the co-author list published on the Google Scholar profile; a collaborator not listed there may be missed, so the independent share below should be read as an **upper bound**. (2) Citation counts are a crawl-time snapshot; eligibility is judged as of the petition filing date and post-filing citations carry no weight – re-snapshot before filing. (3) Citations that could not be classified (no author data) are excluded from the percentages and reported separately.

## B. Citation Independence

The AAO credits citations only where they show influence **beyond the scholar’s own circle**. Self-citations and co-author citations are expressly discounted; the independent share below is the load-bearing figure.

**100.0% independent** of 2 classified citing papers

Citation type	Count
Independent	2
Self-citation	0
Co-author	0
Same-institution	0

62 citing papers could not be classified (no author data) and are excluded from the percentages above.

## C. Significant Contributions & Their Citation Evidence

Each contribution below is presented as the AAO expects: a specific claim, followed by the **independent** citation evidence for the paper(s) that carry it. Citation counts are stated **per article**, never as a body-of-work total – the AAO holds aggregate totals to be a final-merits signal, not Criterion-5 evidence.

Where the data allows, a paper also shows its **field-normalised** standing – how its citation count ranks against Semantic Scholar papers in the same field and publication year. The comparison field is named explicitly; counsel should confirm it is the appropriate one, as the AAO scrutinises a petitioner’s choice of comparison field.

## Contribution 1

### Claim – Contribution 1

*The researcher advanced the understanding of immunotherapy as a promising alternative therapeutic approach against cancers, establishing a foundational reference point in molecular biology reports.*

The researcher's contribution centers on the 2022 paper 'Immunotherapy: an alternative promising therapeutic approach against cancers,' published in Molecular Biology Reports. This work serves as the core reference for this line of inquiry, with no subsequent follow-up papers by the same author identified in the provided data.

This line of work appears to address the need for viable alternative treatments in oncology. By framing immunotherapy as a promising approach, the researcher likely contributed to the broader discourse on shifting therapeutic paradigms away from traditional methods, as suggested by the paper's title and its publication in a specialized molecular biology venue.

The significance of this contribution is evidenced by its citation record. With 114 citations, the paper has garnered substantial attention within the scientific community. Notably, 100% of the classified citing papers originate from independent researchers, indicating that the work has influenced scholars outside the author's immediate institutional or collaborative network, thereby demonstrating independent recognition and impact.

### INDEPENDENT CITATIONS FOR THIS CONTRIBUTION: 2

#### CORE PAPER

#### [Immunotherapy: an alternative promising therapeutic approach against cancers](#)

2022 · Molecular Biology Reports · 114 citations (GS)

Field-normalised: 68 Semantic Scholar citations place it in the top 5% of Medicine papers from 2022 indexed by Semantic Scholar, by citation count.

No.	Citing paper	Citing institution(s)	Country	S2
1	<a href="#">Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery</a> (2025)	Elizabeth City State University, Galala University, Misr University for Science and Technology	Egypt, Germany, United States	—
2	<a href="#">Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions</a>	Barts and The London School of Medicine and Dentistry, Queen Mary University of London	United Kingdom	—

Independent citing papers only; self- and co-author citations excluded. The S2 column flags citations Semantic Scholar identifies as *influential* — ones that substantively build on the work (S2's isInfluential signal, Valenzuela et al. 2015) — the "built on / relied upon" pattern the AAO credits. Counsel should quote the citing text for the strongest of these.

## D. Citing-Institution Prestige & Geography

### Top citing institutions

Institution	Country	World ranking	Citing papers
The Ohio State University Wexner Medical Center	United States	SCImago #669	1
Misr University for Science and Technology	Egypt	SCImago #5944 · THE 1501+	1

Institution	Country	World ranking	Citing papers
National Oceanic and Atmospheric Administration	United States	SCImago #825	1
Galala University	Egypt	SCImago #8879	1
Elizabeth City State University	United States	—	1
Philipps University Marburg	Germany	—	1
Barts and The London School of Medicine and Dentistry, Queen Mary University of London	United Kingdom	—	1

## Geographic distribution of citing authors

Country	Citing papers
Egypt	1
Germany	1
United Kingdom	1
United States	1

Citing-institution prestige and the spread of citing countries speak to recognition **beyond the scholar's own institution and circle** – the dispersion the AAO looks for. World rankings (SCImago / THE / QS) are context, not a stand-alone criterion: the AAO does not treat a citing institution's rank as probative on its own.

## F. AAO Precedent Considerations

### Pre-filing self-check (AAO denial patterns)

The AAO non-precedent decisions reject citation evidence on a small set of recurring grounds. Confirm the petition addresses each before filing:

- Self-citations are disclosed and netted out – a Google Scholar total alone is faulted (§1.1).
- Evidence is per individual article, not a body-of-work aggregate total (§1.2).
- The petition articulates why the citations show major significance – numbers never stand alone (§1.5).
- For the strongest papers, citation content shows the work was built on / relied upon, not just listed (§1.6, §2.2).
- Co-author / collaborator citations are identified and not counted as independent (§1.7).
- Recognition is shown beyond the scholar's own institution and circle (§1.8).
- Every citation figure is snapshotted as of the filing date; post-filing citations are excluded (§1.9).
- Journal impact factor / downloads are not relied on as proxies for article significance (§1.10, §1.12).
- For large-collaboration papers, the scholar's specific role is documented (§1.13).
- Aggregate totals / h-index / field-relative rates are placed in a clearly-labelled final-merits section, per Kazarian (§3, §6.1.7).

### Disclaimer

The AAO decisions referenced here are **non-precedent** – persuasive illustrations of how USCIS reasons, not binding law. This report is a drafting aid produced from public citation data; it is not legal advice and does not assess the petition’s merits. All analysis must be reviewed by qualified immigration counsel.

## G. Citation Evidence Index

---

Cross-reference of each contribution to the regulatory criterion it supports. Counsel should map these to the petition’s exhibit numbers.

<b>Contribution</b>	<b>Core paper</b>	<b>Indep. cites</b>	<b>Supports</b>
Contribution 1	Immunotherapy: an alternative promising therapeutic approach against cancers	2	8 CFR 204.5(h)(3)(v) – Criterion 5